These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 8030735)
1. Plasminogen activator of urokinase type and its inhibitor of placental type in hypertensive pregnancies and in intrauterine growth retardation: possible markers of placental function. Lindoff C; Astedt B Am J Obstet Gynecol; 1994 Jul; 171(1):60-4. PubMed ID: 8030735 [TBL] [Abstract][Full Text] [Related]
2. Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia. Estellés A; Gilabert J; España F; Aznar J; Galbis M Am J Obstet Gynecol; 1991 Jul; 165(1):138-42. PubMed ID: 1906680 [TBL] [Abstract][Full Text] [Related]
3. Placental-type plasminogen activator inhibitor in preeclampsia. de Boer K; Lecander I; ten Cate JW; Borm JJ; Treffers PE Am J Obstet Gynecol; 1988 Mar; 158(3 Pt 1):518-22. PubMed ID: 3126658 [TBL] [Abstract][Full Text] [Related]
4. Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia. Roes EM; Sweep CG; Thomas CM; Zusterzeel PL; Geurts-Moespot A; Peters WH; Steegers EA Am J Obstet Gynecol; 2002 Oct; 187(4):1019-25. PubMed ID: 12388999 [TBL] [Abstract][Full Text] [Related]
5. Significance of the plasminogen activator inhibitor of placental type (PAI-2) in pregnancy. Astedt B; Lindoff C; Lecander I Semin Thromb Hemost; 1998; 24(5):431-5. PubMed ID: 9834009 [TBL] [Abstract][Full Text] [Related]
6. Placental ratio in pregnancies at different risk for intrauterine growth. Bortolus R; Chatenoud L; Di Cintio E; Rossi P; Benzi G; Surace M; Parazzini F Eur J Obstet Gynecol Reprod Biol; 1998 Oct; 80(2):157-8. PubMed ID: 9846659 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of plasminogen activators and plasminogen activator inhibitors in plasma and amniotic fluid in pregnancies complicated with intrauterine fetal growth retardation. Gilabert J; Estellés A; Ayuso MJ; España F; Chirivella M; Grancha S; Micó JM; Aznar J Gynecol Obstet Invest; 1994; 38(3):157-62. PubMed ID: 8001867 [TBL] [Abstract][Full Text] [Related]
8. Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors. Nakashima A; Kobayashi T; Terao T Gynecol Obstet Invest; 1996; 42(2):95-101. PubMed ID: 8878712 [TBL] [Abstract][Full Text] [Related]
9. Quantitative structural studies on human placentas associated with pre-eclampsia, essential hypertension and intrauterine growth retardation. Boyd PA; Scott A Br J Obstet Gynaecol; 1985 Jul; 92(7):714-21. PubMed ID: 4016032 [TBL] [Abstract][Full Text] [Related]
11. An ultrastructural study of utero-placental spiral arteries in hypertensive and normotensive pregnancy and fetal growth retardation. Sheppard BL; Bonnar J Br J Obstet Gynaecol; 1981 Jul; 88(7):695-705. PubMed ID: 7248226 [TBL] [Abstract][Full Text] [Related]
12. Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation. Schjetlein R; Haugen G; Wisløff F Acta Obstet Gynecol Scand; 1997 Jul; 76(6):541-6. PubMed ID: 9246959 [TBL] [Abstract][Full Text] [Related]
13. Decreased expression of PAI-2 mRNA and protein in pregnancies complicated with intrauterine fetal growth retardation. Grancha S; Estellés A; Gilabert J; Chirivella M; España F; Aznar J Thromb Haemost; 1996 Nov; 76(5):761-7. PubMed ID: 8950787 [TBL] [Abstract][Full Text] [Related]
14. Angiogenic and fibrinolytic factors in blood during the first half of pregnancy and adverse pregnancy outcomes. Coolman M; Timmermans S; de Groot CJ; Russcher H; Lindemans J; Hofman A; Geurts-Moespot AJ; Sweep FC; Jaddoe VV; Steegers EA Obstet Gynecol; 2012 Jun; 119(6):1190-200. PubMed ID: 22617584 [TBL] [Abstract][Full Text] [Related]
15. Increased human placental growth hormone at midtrimester pregnancies may be an index of intrauterine growth retardation related to preeclampsia. Papadopoulou E; Sifakis S; Giahnakis E; Fragouli Y; Karkavitsas N; Koumantakis E; Kalmanti M Growth Horm IGF Res; 2006; 16(5-6):290-6. PubMed ID: 16996762 [TBL] [Abstract][Full Text] [Related]
16. Changes of dimeric inhibin B levels in maternal serum throughout healthy gestation and in women with gestational diseases. Petraglia F; Luisi S; Benedetto C; Zonca M; Florio P; Casarosa E; Volpe A; Bernasconi S; Genazzani AR J Clin Endocrinol Metab; 1997 Sep; 82(9):2991-5. PubMed ID: 9284732 [TBL] [Abstract][Full Text] [Related]
17. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Estellés A; Gilabert J; Keeton M; Eguchi Y; Aznar J; Grancha S; Espña F; Loskutoff DJ; Schleef RR Blood; 1994 Jul; 84(1):143-50. PubMed ID: 8018914 [TBL] [Abstract][Full Text] [Related]
18. Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathologic features. Salafia CM; Minior VK; Pezzullo JC; Popek EJ; Rosenkrantz TS; Vintzileos AM Am J Obstet Gynecol; 1995 Oct; 173(4):1049-57. PubMed ID: 7485292 [TBL] [Abstract][Full Text] [Related]
19. First-trimester placental thickness and the risk of preeclampsia or SGA. Vachon-Marceau C; Demers S; Markey S; Okun N; Girard M; Kingdom J; Bujold E Placenta; 2017 Sep; 57():123-128. PubMed ID: 28864000 [TBL] [Abstract][Full Text] [Related]
20. Endoglin in pregnancy complicated by fetal intrauterine growth restriction in normotensive and preeclamptic pregnant women: a comparison between preeclamptic patients with appropriate-for-gestational-age weight infants and healthy pregnant women. Laskowska M; Laskowska K; Oleszczuk J J Matern Fetal Neonatal Med; 2012 Jun; 25(6):806-11. PubMed ID: 21793708 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]